@americanaging.bsky.socialNew npj Aging consensus paper: researchers are proposing standardized biomarker data collection for longevity biotech trials — because right now, results from different companies' trials can't even be meaningfully compared 🧬📋
doi.org/10.1038/s415...
#GeroScience #AgingBiomarkers #LongevityBiotech
@americanaging.bsky.socialLongevity biotech raised ~$3.74B across 49 deals in Q1 2026 alone — up 56% YoY. Capital is increasingly targeting the underlying biology of aging itself, not just its symptoms (Forbes, data via Longevity.Technology/PitchBook)
www.forbes.com/sites/darias...
@longevitytech.bsky.socialInside the $230 billion our new *Longevity Biotech Report* says the pipeline is already worth – no regulatory rewrite required.
Link as first comment.
@longevitytech.bsky.socialOur new Longevity Biotech Report puts a number on longevity’s payoff – and asks who actually gets to cash it in.
Link as first comment.
@longevitytech.bsky.socialLongevity biotech is now a market.
The Longevity Biotech Report 2026 tracks 3,036 assets across 781 companies and projects a $617BN annual market by 2045.
Read more about it in the comment below.
Sponsored by MuseCell Innovations.
